All of us who read the story about the more-than-5000-percent increase in the price of Daraprim [ht: ja] wanted to know why.
Apparently, our moronic outrage has caused CEO Martin Shkreli to reconsider.
“Yes it is absolutely a reaction — there were mistakes made with respect to helping people understand why we took this action, I think that it makes sense to lower the price in response to the anger that was felt by people,” Shkreli, 32, said.
Turing Pharmaceuticals of New York bought the drug from Impax Laboratories in August for $55 million and raised the price. Shkreli said Tuesday the price would be lowered to allow the company to break even or make a smaller profit.